Share-based Payment Arrangement, Expense of AGIOS PHARMACEUTICALS, INC. from 31 Dec 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
AGIOS PHARMACEUTICALS, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2011 to 30 Sep 2025.
  • AGIOS PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $12,377,000, a 11% increase year-over-year.
  • AGIOS PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $49,331,000, a 7.8% increase year-over-year.
  • AGIOS PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $42,847,000, a 4.3% decline from 2023.
  • AGIOS PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $44,766,000, a 9.2% decline from 2022.
  • AGIOS PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2022 was $49,296,000, a 7.9% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

AGIOS PHARMACEUTICALS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $49,331,000 $12,377,000 +$1,232,000 +11% 01 Jul 2025 30 Sep 2025 10-Q 30 Oct 2025 2025 Q3
Q2 2025 $48,099,000 $14,692,000 +$3,127,000 +27% 01 Apr 2025 30 Jun 2025 10-Q 31 Jul 2025 2025 Q2
Q1 2025 $44,972,000 $11,359,000 +$2,125,000 +23% 01 Jan 2025 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q4 2024 $42,847,000 $10,903,000 -$2,911,000 -21% 01 Oct 2024 31 Dec 2024 10-K 13 Feb 2025 2024 FY
Q3 2024 $45,758,000 $11,145,000 +$2,069,000 +23% 01 Jul 2024 30 Sep 2024 10-Q 30 Oct 2025 2025 Q3
Q2 2024 $43,689,000 $11,565,000 -$172,000 -1.5% 01 Apr 2024 30 Jun 2024 10-Q 31 Jul 2025 2025 Q2
Q1 2024 $43,861,000 $9,234,000 -$905,000 -8.9% 01 Jan 2024 31 Mar 2024 10-Q 01 May 2025 2025 Q1
Q4 2023 $44,766,000 $13,814,000 +$2,349,000 +20% 01 Oct 2023 31 Dec 2023 10-K 13 Feb 2025 2024 FY
Q3 2023 $42,417,000 $9,076,000 -$2,080,000 -19% 01 Jul 2023 30 Sep 2023 10-Q 31 Oct 2024 2024 Q3
Q2 2023 $44,497,000 $11,737,000 +$572,000 +5.1% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $43,925,000 $10,139,000 -$5,371,000 -35% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $49,296,000 $11,465,000 -$156,000 -1.3% 01 Oct 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
Q3 2022 $49,452,000 $11,156,000 -$992,000 -8.2% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $50,444,000 $11,165,000 -$3,720,000 -25% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $54,164,000 $15,510,000 +$656,000 +4.4% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $53,508,000 $11,621,000 -$1,720,000 -13% 01 Oct 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
Q3 2021 $55,228,000 $12,148,000 -$2,829,000 -19% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $58,057,000 $14,885,000 -$2,729,000 -15% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $60,786,000 $14,854,000 -$816,000 -5.2% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $61,602,000 $13,341,000 +$10,534,000 +375% 01 Oct 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
Q3 2020 $51,068,000 $14,977,000 -$3,611,000 -19% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 $54,679,000 $17,614,000 -$933,000 -5% 01 Apr 2020 30 Jun 2020 10-Q 29 Jul 2021 2021 Q2
Q1 2020 $55,612,000 $15,670,000 -$2,438,000 -13% 01 Jan 2020 31 Mar 2020 10-Q 29 Apr 2021 2021 Q1
Q4 2019 $58,050,000 $2,807,000 -$15,380,000 -85% 01 Oct 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
Q3 2019 $73,430,000 $18,588,000 -$5,605,000 -23% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $79,035,000 $18,547,000 +$2,092,000 +13% 01 Apr 2019 30 Jun 2019 10-Q 30 Jul 2020 2020 Q2
Q1 2019 $76,943,000 $18,108,000 +$3,586,000 +25% 01 Jan 2019 31 Mar 2019 10-Q 30 Apr 2020 2020 Q1
Q4 2018 $73,357,000 $18,187,000 +$5,506,000 +43% 01 Oct 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
Q3 2018 $67,851,000 $24,193,000 +$11,986,000 +98% 01 Jul 2018 30 Sep 2018 10-Q 31 Oct 2019 2019 Q3
Q2 2018 $55,865,000 $16,455,000 +$4,268,000 +35% 01 Apr 2018 30 Jun 2018 10-Q 01 Aug 2019 2019 Q2
Q1 2018 $51,597,000 $14,522,000 +$3,788,000 +35% 01 Jan 2018 31 Mar 2018 10-Q 02 May 2019 2019 Q1
Q4 2017 $47,809,000 $12,681,000 +$2,841,000 +29% 01 Oct 2017 31 Dec 2017 10-K 19 Feb 2020 2019 FY
Q3 2017 $44,968,000 $12,207,000 +$64,000 +0.53% 01 Jul 2017 30 Sep 2017 10-Q 01 Nov 2018 2018 Q3
Q2 2017 $44,904,000 $12,187,000 +$1,191,000 +11% 01 Apr 2017 30 Jun 2017 10-Q 02 Aug 2018 2018 Q2
Q1 2017 $43,713,000 $10,734,000 +$1,627,000 +18% 01 Jan 2017 31 Mar 2017 10-Q 04 May 2018 2018 Q1
Q4 2016 $42,086,000 $9,840,000 +$486,000 +5.2% 01 Oct 2016 31 Dec 2016 10-K 14 Feb 2019 2018 FY
Q3 2016 $41,600,000 $12,143,000 +$2,771,000 +30% 01 Jul 2016 30 Sep 2016 10-Q 01 Nov 2017 2017 Q3
Q2 2016 $38,829,000 $10,996,000 +$2,819,000 +34% 01 Apr 2016 30 Jun 2016 10-Q 08 Aug 2017 2017 Q2
Q1 2016 $36,010,000 $9,107,000 +$4,047,000 +80% 01 Jan 2016 31 Mar 2016 10-Q 04 May 2017 2017 Q1
Q4 2015 $31,963,000 $9,354,000 +$4,626,000 +98% 01 Oct 2015 31 Dec 2015 10-K 14 Feb 2018 2017 FY
Q3 2015 $27,337,000 $9,372,000 +$6,480,000 +224% 01 Jul 2015 30 Sep 2015 10-Q 03 Nov 2016 2016 Q3
Q2 2015 $20,857,000 $8,177,000 +$5,796,000 +243% 01 Apr 2015 30 Jun 2015 10-Q 08 Aug 2016 2016 Q2
Q1 2015 $15,061,000 $5,060,000 +$3,555,000 +236% 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016 2016 Q1
Q4 2014 $11,506,000 $4,728,000 +$3,563,000 +306% 01 Oct 2014 31 Dec 2014 10-K 16 Feb 2017 2016 FY
Q3 2014 $7,943,000 $2,892,000 +$1,780,000 +160% 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2015 2015 Q3
Q2 2014 $6,163,000 $2,381,000 +$2,052,000 +624% 01 Apr 2014 30 Jun 2014 10-Q 07 Aug 2015 2015 Q2
Q1 2014 $4,111,000 $1,505,000 +$1,081,000 +255% 01 Jan 2014 31 Mar 2014 10-Q 11 May 2015 2015 Q1
Q4 2013 $3,030,000 $1,165,000 01 Oct 2013 31 Dec 2013 10-K 26 Feb 2016 2015 FY
Q3 2013 $1,112,000 +$942,000 +554% 01 Jul 2013 30 Sep 2013 10-Q 07 Nov 2014 2014 Q3
Q2 2013 $329,000 +$238,000 +262% 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014 2014 Q2
Q1 2013 $424,000 01 Jan 2013 31 Mar 2013 10-Q 09 May 2014 2014 Q1
Q3 2012 $170,000 01 Jul 2012 30 Sep 2012 10-Q 07 Nov 2013 2013 Q3
Q2 2012 $91,000 01 Apr 2012 30 Jun 2012 10-Q 05 Sep 2013 2013 Q2

AGIOS PHARMACEUTICALS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $42,847,000 -$1,919,000 -4.3% 01 Jan 2024 31 Dec 2024 10-K 13 Feb 2025 2024 FY
2023 $44,766,000 -$4,530,000 -9.2% 01 Jan 2023 31 Dec 2023 10-K 13 Feb 2025 2024 FY
2022 $49,296,000 -$4,212,000 -7.9% 01 Jan 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
2021 $53,508,000 -$8,094,000 -13% 01 Jan 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
2020 $61,602,000 +$3,552,000 +6.1% 01 Jan 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
2019 $58,050,000 -$15,307,000 -21% 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
2018 $73,357,000 +$25,548,000 +53% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
2017 $47,809,000 +$5,723,000 +14% 01 Jan 2017 31 Dec 2017 10-K 19 Feb 2020 2019 FY
2016 $42,086,000 +$10,123,000 +32% 01 Jan 2016 31 Dec 2016 10-K 14 Feb 2019 2018 FY
2015 $31,963,000 +$20,457,000 +178% 01 Jan 2015 31 Dec 2015 10-K 14 Feb 2018 2017 FY
2014 $11,506,000 +$8,476,000 +280% 01 Jan 2014 31 Dec 2014 10-K 16 Feb 2017 2016 FY
2013 $3,030,000 +$2,288,000 +308% 01 Jan 2013 31 Dec 2013 10-K 26 Feb 2016 2015 FY
2012 $742,000 +$371,000 +100% 01 Jan 2012 31 Dec 2012 10-K 24 Feb 2015 2014 FY
2011 $371,000 01 Jan 2011 31 Dec 2011 10-K 18 Mar 2014 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.